We are testing a new medication for people with idiopathic immune complex mediated membranoproliferative glomerulonephritis to see if it reduces protein in urine and improves kidney function. The study also evaluates how well patients feel while using this treatment.
Health conditions and diseases that the clinical trial is designed to study and treat.
Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN) is a rare kidney disease characterized by inflammation and damage to the kidney's filtering units, often leading to symptoms such as swelling, high blood pressure, and changes in urine output.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
